Urinary Incontinence
Conditions
Keywords
Female urinary incontinence, Sphincter deficiency
Brief summary
The main objective is to compare the efficacy of AMS800 ™ and ACT ™ devices for the Treatment of Female Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency on social continence at 6 months. Continence is defined by the average number of pads used per day. The social continence is defined by (0-1) pad per day
Detailed description
Prospective multicenter randomized controlled trial comparing two parallel arms: the implantation of an adjustable balloon (experimental arm) versus implantation of an artificial urinary sphincter AMS800 ™ (control arm), for the treatment of female stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). This research will focus on the assessment of improved continence, quality of life, and Cost-Effectiveness Analysis. The tested device ACT ™ device is a prosthesis used to support the bladder neck and proximal urethra increasing the urethral coaptation and supporting to the bladder neck to prevent urine leakage at stress. The medical device AMS 800 ™(control arm) is an implantable device made of silicone elastomer filled with saline/X-Ray fluid, used in the treatment of stress urinary incontinence related to ISD. It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by closing the urethra and allowing the patient to void according to the patient's will and opening of the device (sub-cutaneous pump). An inclusion visit will take place between 3 months and 1 month before the date of the surgery to explain the purpose of the study, the benefits and risks for patients, and describe the comparative medical devices. Patients will be randomized before surgery (at D0). The follow-up will be conducted up to one year, with scheduled visits at M1, M3, M6 and M12. Secondary endpoints will be assessed during scheduled visits. The medico-economic assessment will be made during the same follow-up period. This period will take into account improvement of urinary continence and results reported from the 3rd month as well as the morbidity and mortality related to the implementation of the medical device up to 1 year. .
Interventions
DEVICEACT™ device
Implantation of the Adjustable Continence Therapy device ACT®
DEVICEAMS 800 ™ device
Implantation of the artificial urinary sphincter AMS 800 ™
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients suffering from stress urinary incontinence due to ISD. * Patients with maximum urethral closure pressure(PCUM) \< 50 cm H2O or bladder leakage pressure \< 100 cm H2O * Patient who accepted surgery * Patient with normal urethra-cystoscopy (no foreign body nor calculus) * Patient with effort leaks on clinical examination * Patient who never had SUA or ACT ™ balloon * Affiliation to health insurance * Written informed consent
Exclusion criteria
* Patient pregnant or breastfeeding * Patient with a life expectancy of less than 2 years * Patient with overactive bladder uncontrolled and considered an against-indication for surgery * Patient with reduced bladder compliance * Patient with significant post-void residual volume according to the judgment of the Investigator * Patient with a history of pelvic radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Social continence defined by the use of 0-1 adult protective pads per day | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of incontinence (number and type of protective pads used per day) | 12 months |
| impact on quality of life assessed by EQ-5D Health Questionnaire. | 12 months |
| assessment of the urinary flow using ICIQ-FLUTS questionnaire | 12 months |
| Assessment of Urinary Profile Symptoms using UPS questionnaire | 12 months |
Countries
France
Contacts
Primary ContactCHARTIER-KASTLER EMMANUEL, MD, PhD
Outcome results
None listed